Related Experiment Videos
Cardiovascular pathophysiology of essential hypertension: a clue to therapy
Insights
Essential hypertension presents in distinct patient subsets, each requiring tailored antihypertensive therapies. Enalapril, an ACE inhibitor, effectively reduces total peripheral resistance for broad application in managing high blood pressure.
Area of Science:
- Cardiovascular Pathophysiology
- Pharmacology of Hypertension
Background:
- Arterial hypertension is a hemodynamic disorder with distinct pathophysiological profiles.
- Essential hypertension manifests in three primary subsets: young lean, elderly, and obese/black patients.
- Each subset exhibits unique hemodynamic characteristics, including cardiac output, peripheral resistance, and fluid volume status.
Purpose of the Study:
- To delineate the distinct pathophysiological subsets of essential hypertension.
- To identify appropriate first-line antihypertensive drug choices for each patient subset.
- To evaluate the role of enalapril, a novel angiotensin-converting enzyme (ACE) inhibitor, in managing hypertension.
Main Methods:
- Classification of hypertensive patients into young lean, elderly, and obese/black phenotypes based on hemodynamic profiles.
- Review of established and emerging antihypertensive treatment strategies for each identified subset.
- Analysis of enalapril's hemodynamic effects, including preload, afterload, and systemic/regional blood flow.
Main Results:
- Young lean patients benefit from beta-adrenergic receptor blockers.
- Elderly patients are best treated with hemodynamic vasodilators (e.g., ACE inhibitors).
- Obese and black patients typically respond well to thiazide diuretics.
- Enalapril effectively reduces total peripheral resistance without compromising blood flow and improves cardiac function in elderly patients with heart failure.
Conclusions:
- Tailoring antihypertensive therapy to specific patient pathophysiological subsets is crucial for effective management.
- Enalapril is a versatile first-step agent for reducing arterial pressure by decreasing total peripheral resistance.
- Enalapril offers unique benefits in managing elderly hypertensive patients, including those with heart failure, by reducing cardiac preload and afterload.
Abstract:
Arterial hypertension is by definition a haemodynamic disorder. At least 3 different subsets of cardiovascular pathophysiological features can be identified in so-called essential hypertension: The young lean patient characterised by an elevated cardiac output and renal blood flow, elevated plasma renin activity and circulating catecholamine levels, as well as symptoms and signs of hyperadrenergic hypertension. The elderly patient characterised by a low cardiac output often with left ventricular hypertrophy, elevated total peripheral resistance, nephrosclerosis, and symptoms and signs of target organ disease. The obese patient (and to a lesser degree the black patient) characterised by expanded fluid volume state, elevated cardiac output, a normal to low total peripheral resistance, and symptoms and signs of volume overload. To initiate antihypertensive therapy, the drug of choice in the young patient is a beta-adrenergic receptor blocker; in the elderly it is a haemodynamic vasodilator (anti-adrenergic drug, slow channel calcium blocker, or converting enzyme (ACE) inhibitor), and in black or obese patients it remains a thiazide diuretic. Enalapril, a new ACE inhibitor is indicated as a first-step agent in the great majority of hypertensive patients in whom the elevated arterial pressure should be reduced by a decrease in total peripheral resistance, without compromising systemic or regional blood flow. In contrast to other antihypertensive agents, enalapril will lower preload and afterload to the left ventricle while improving systemic and regional flow in elderly patients with latent or manifest congestive heart failure.